US-Listed In Vitro & In Vivo Diagnostic Substances — Operating Income Percentiles, FY 2024

Population: 18 US-listed companies (SIC 2835), fiscal year 2024; fiscal year ends 2024-12-29 to 2025-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$-692.3M
25th percentile	$-107.9M
Median	$-17.3M
75th percentile	$-2.5M
90th percentile	$138.5M
Mean	$-136.8M
Minimum	$-2.0B
Maximum	$1.1B

Methodology & sources
Operating Income as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2024 = fiscal years ending 2024-06-01 to 2025-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Operating Income percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/operating-income/2024